Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1
antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with
unresectable hepatocellular carcinoma.